Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Vor Biopharma, a US-based developer of treatments for haematological malignancies based on research at Columbia University, has filed for a $150m initial public offering.
Founded in 2015, Vor is working on drug treatments for haematological malignancies, a type of cancer that affects the blood, bone marrow and lymph nodes. Part of the IPO proceeds will fund the completion of a phase 1/2a clinical trial for its lead drug candidate, VOR33,
The company also plans to invest in…
